Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Omar, Dabbous"'
Autor:
Victoria W. Dayer, Michael F. Drummond, Omar Dabbous, Mondher Toumi, Peter Neumann, Sean Tunis, Nelson Teich, Shadi Saleh, Ulf Persson, Johann-Matthias Graf von der Schulenburg, Daniel C. Malone, Tay Salimullah, Sean D. Sullivan
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-12 (2024)
Abstract Health technology assessment (HTA) decisions for pharmaceuticals are complex and evolving. New rare disease treatments are often approved more quickly through accelerated approval schemes, creating more uncertainties about clinical evidence
Externí odkaz:
https://doaj.org/article/18f7fcfcb90a4c4685fa9f6e8e16039b
Autor:
Mondher Toumi, Omar Dabbous, Samuel Aballéa, Michael F. Drummond, Johann-Matthias Graf von der Schulenburg, Daniel C. Malone, Peter J. Neumann, Sean D. Sullivan, Sean Tunis
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 23:483-497
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a17e9cb0f682ecfc14609f238695b368
https://doi.org/10.1080/14737167.2023.2197214
https://doi.org/10.1080/14737167.2023.2197214
Publikováno v:
Value in Health. 26:336-343
Conventional cost-effectiveness analysis (CEA) for the value-based pricing of new medicines largely ignores the implications of limited market exclusivity (ie, patent-protection periods plus any exclusivity granted by regulators). This paper explores
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e98b18b1ec2531cc1683143148c04d
https://doi.org/10.1016/j.jval.2022.09.010
https://doi.org/10.1016/j.jval.2022.09.010
Autor:
Rebecca Dean, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Thomas Wiesner, Daniel C. Malone, Matthias Bischof, Walter Toro, Omar Dabbous
Publikováno v:
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Background: Recent cost-utility analysis (CUA) models for onasemnogene abeparvovec (Zolgensma®, formerly AVXS-101) in spinal muscular atrophy type 1 (SMA1) differ on key assumptions and results. Objective: To compare the manufacturer’s proprietary
Externí odkaz:
https://doaj.org/article/4ff5f47c0a944bf891888597b331385c
Publikováno v:
Journal of Market Access & Health Policy, Vol 8, Iss 1 (2020)
Background: Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disease. Objective: Characterize direct costs associated with SMA management. Data source: Truven Health Analytics MarketScan claims data (2012–2016). Patients: Eligible pati
Externí odkaz:
https://doaj.org/article/57e6b65dc4854a7c881414149697dc1e
Autor:
Samuel Aballéa, Katia Thokagevistk, Rimma Velikanova, Steven Simoens, Lieven Annemans, Fernando Antonanzas, Pascal Auquier, Clément François, Frank-Ulrich Fricke, Daniel Malone, Aurélie Millier, Ulf Persson, Stavros Petrou, Omar Dabbous, Maarten Postma, Mondher Toumi
Publikováno v:
Journal of Market Access & Health Policy, Vol 8, Iss 1 (2020)
Objective: To provide recommendations for addressing previously identified key challenges in health economic evaluations of Gene Replacement Therapies (GRTs), including: 1) the assessment of clinical effectiveness; 2) the valuation of health outcomes
Externí odkaz:
https://doaj.org/article/94468d6f449f4f42bffe48594a3cb1c3
Autor:
Daniel C. Malone, Rebecca Dean, Ramesh Arjunji, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Omar Dabbous
Publikováno v:
Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)
Background: Spinal muscular atrophy type 1 (SMA1) is a devastating genetic disease for which gene-replacement therapy may bring substantial survival and quality of life benefits. Objective: This study investigated the cost-effectiveness of onasemnoge
Externí odkaz:
https://doaj.org/article/930a9177e655400d90828ef1a4362fd9
Autor:
Omar Dabbous, Min Yang, Mihaela Georgieva, Walter Toro, Nicole LaMarca, Anish Patel, Annika Anderson, Hanane Akbarnejad, Sandra P. Reyna
Publikováno v:
Tuesday, April 25.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83cca7f50acf86e0123b0969bf3375d9
https://doi.org/10.1212/wnl.0000000000202541
https://doi.org/10.1212/wnl.0000000000202541
Autor:
Omar Dabbous, Lylia Chachoua, Samuel Aballéa, Marine Sivignon, Ulf Persson, Stavros Petrou, Jeff Richardson, Steven Simoens, Mondher Toumi
Publikováno v:
Advances in therapy.
We sought to synthesize published empirical studies that elicited and characterized societal valuations of orphan drugs and the attributes that may drive different valuations for orphan drugs versus other treatments.We conducted a systematic literatu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c80934f0b75d20f40ffe7d45ef5849c5
https://pubmed.ncbi.nlm.nih.gov/36451072
https://pubmed.ncbi.nlm.nih.gov/36451072
Publikováno v:
Value in Health. 25:1922-1923
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e28820205d15e77ed1abc4b7625c523a
https://doi.org/10.1016/j.jval.2021.10.019
https://doi.org/10.1016/j.jval.2021.10.019